MilliporeSigma Opens Production Facility in Mollet des Vallès

January 17, 2017

The company opened a facility in Spain dedicated to the production of meglumine.

On Jan. 17, 2017, MilliporeSigma announced the opening of a facility in Mollet des Vallès, Spain dedicated to the manufacture of meglumine, an FDA-approved excipient for pharmaceuticals and a component of medical imaging contrast media. The FDA-validated facility in Spain is solely dedicated to the production of meglumine, an amino sugar derived from glucose. As an excipient, meglumine interacts directly with APIs to increase solubility. Therefore, the manufacture of meglumine must meet the same stringent regulatory and quality requirements as APIs, the company said in a statement.

This follows an announcement made by the company on Jan. 10, 2017 on the opening of two new bioprocessing centers. The new locations, in Boston, MA and China, will offer cell-line development services, process development expertise, and non-GMP clinical production services.

Source: MilliporeSigma